Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zenas BioPharmaZBIO -1.94%12 Buyback Yield % is -8.62 as of Jul. 25, 2026. GuruFocus rates ZBIO with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 738 Biotechnology companies, Zenas BioPharma ranks better than 52.03% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Zenas BioPharma's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ZBIO vs AKTS, MLTX, FTRE: Buyback Yield % Comparison
For the Biotechnology subindustry, Zenas BioPharma's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zenas BioPharma Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zenas BioPharma's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Zenas BioPharma's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zenas BioPharma (ZBIO) has a Buyback Yield % of -8.62 as of Jul. 25, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Zenas BioPharma and its competitors. According to the industry distribution chart, Zenas BioPharma ranks #354 out of 738 companies in the Biotechnology industry, placing it in the top 48%.
Is Zenas BioPharma's Buyback Yield % too high?
Zenas BioPharma's current Buyback Yield % is -8.62. Based on the distribution chart, Zenas BioPharma ranks #354 out of 738 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Zenas BioPharma has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Zenas BioPharma's Buyback Yield % compare to AKTS and MLTX?
According to the Biotechnology industry distribution chart, Zenas BioPharma ranks #354 out of 738 companies for Buyback Yield %. This puts Zenas BioPharma in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Zenas BioPharma and its competitors. Zenas BioPharma's current Buyback Yield % is -8.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zenas BioPharma stock overvalued right now?
Zenas BioPharma (ZBIO) has a current Buyback Yield % of -8.62. The current Buyback Yield % is -8.62. Zenas BioPharma's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Zenas BioPharma (ZBIO), the current Buyback Yield % is -8.62 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.
12GF Score
Get the complete analysis for ZBIO
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZBIO has been successfully added to your 
